A gene that’s associated with an autoimmune form of hair loss could be exploited to improve cancer immunotherapy, suggests a new mouse study.
Browsing: Disease Area > Skin
Checkpoint inhibitors increase median survival to 12.4 months, and more than double percentage of patients who survive 4 years or longer.
Choosing when to stop immunotherapy is an extremely difficult decision process – in this blog piece melanoma survivor T.J. Sharpe shares his thoughts on the recent KEYNOTE-006 data.
Keep checking back throughout the conference, we will be updating this article with the biggest news headlines from the American Association for Cancer Research (AACR) Annual Meeting 2018 (April 14–18, IL, USA).
Positive late-stage data has been announced from the KEYNOTE-054 trial, investigating KEYTRUDA® (pembrolizumab) in high-risk stage III melanoma patients.
Delve deeper into the promising PD-L1 research being published, in this patient perspective piece from Stage IV melanoma patient T.J. Sharpe.
Researchers have discovered that anti-PD-1/PD-L1 therapies are highly effective in patients with desmoplastic melanoma, challenging previous assumptions.
Researchers have presented the association between tumor response and health-related quality of life in patients with metastatic Merkel cell carcinoma treated with avelumab.